Fibrogen Gets Regulator’s Green Light To Sell China Unit To AstraZeneca

The company expects the transaction, which was announced in February, to close in the third quarter of 2025.

FibroGen, Inc. (FGEN) on Monday said that a Chinese regulator has approved the sale of its unit FibroGen International (Hong Kong) to AstraZeneca (AZN).

FibroGen had announced the sale of its China unit to AstraZeneca for about $160 million in February. The closing of the transaction is now expected in the third quarter of 2025, the company said.  

Get updates to this developing story <directly on Stocktwits.<